Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…Abstract Number: 2575 • ACR Convergence 2023
Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Background/Purpose: Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within three years prior to or following IIM onset. The International Guideline…Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…Abstract Number: 1653 • ACR Convergence 2023
Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation (FL) in older adults, with difficulty climbing stairs often the first-reported limitation. Overall increased…Abstract Number: 2220 • ACR Convergence 2023
Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Background/Purpose: Depending on leading manifestation, Spondyloarthritis (SpA) is classified as axial (axSpA) or peripheral SpA (pSpA). Achieving of remission/inactive disease is key goal in treatment…Abstract Number: 2583 • ACR Convergence 2023
A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) substantially increases the risk of developing rheumatoid arthritis (RA). The definition of individuals with arthralgia at…Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…Abstract Number: 2267 • ACR Convergence 2023
Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…Abstract Number: 2588 • ACR Convergence 2023
Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…Abstract Number: 0394 • ACR Convergence 2023
Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study
Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). We aimed to examine the relation between adherence to dietary recommendations and the…Abstract Number: 1063 • ACR Convergence 2023
Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 23
- Next Page »